PMID- 21750865
OWN - NLM
STAT- MEDLINE
DCOM- 20120123
LR  - 20171116
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 26
IP  - 4
DP  - 2011 Oct
TI  - Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors.
PG  - 931-7
LID - 10.3892/or.2011.1384 [doi]
AB  - 4F2hc (CD98) has been associated with tumor growth, and is highly expressed in 
      various tumors. The aim of this study was to evaluate the clinicopathological 
      significance of 4F2hc expression in pulmonary neuroendocrine (NE) tumors. 
      Surgically-resected patient tumors including 16 large cell neuroendocrine 
      carcinoma (LCNEC), 12 small cell lung cancer (SCLC), 1 atypical carcinoid (AC) 
      and 5 typical carcinoid (TC) samples were included in this study. Tumor sections 
      were immunohistochemically stained for 4F2hc (CD98), glucose transporter 1 
      (Glut1) and 3 (Glut3), hypoxia-inducible factor-1alpha (HIF-1alpha), hexokinase I, 
      vascular endothelial growth factor (VEGF), microvessel density (CD34), epidermal 
      growth factor receptor (EGFR), Akt/mammalian target of rapamycin (mTOR) signaling 
      pathway (p-Akt, p-mTOR and p-S6K) and for a cell cycle regulator (p53). 4F2hc was 
      overexpressed in 0% of the pulmonary carcinoids (TCs and ACs), 62.5% of the 
      LCNECs and 50.0% of the SCLCs. A positive 4F2hc expression was significantly 
      associated with age, histology and Glut1 expression. Moreover, a significant 
      correlation was found between 4F2hc expression, and Glut1, HIF-1alpha, p-Akt, p-mTOR 
      and p-S6K. The expression of 4F2hc was also significantly associated with poor 
      overall survival. The expression of 4F2hc expression tended to increase from 
      low-grade to high-grade pulmonary NE tumors. Our results suggest that 4F2hc may 
      play a significant role in tumor progression, hypoxic conditions and poor outcome 
      in patients with pulmonary NE tumors.
FAU - Kaira, Kyoichi
AU  - Kaira K
AD  - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, 
      Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. kkaira1970@yahoo.co.jp
FAU - Ohde, Yasuhisa
AU  - Ohde Y
FAU - Endo, Masahiro
AU  - Endo M
FAU - Nakagawa, Kazuo
AU  - Nakagawa K
FAU - Okumura, Takehiro
AU  - Okumura T
FAU - Takahashi, Toshiaki
AU  - Takahashi T
FAU - Murakami, Haruyasu
AU  - Murakami H
FAU - Tsuya, Asuka
AU  - Tsuya A
FAU - Nakamura, Yukiko
AU  - Nakamura Y
FAU - Naito, Tateaki
AU  - Naito T
FAU - Kondo, Haruhiko
AU  - Kondo H
FAU - Nakajima, Takashi
AU  - Nakajima T
FAU - Yamamoto, Nobuyuki
AU  - Yamamoto N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110711
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Fusion Regulatory Protein 1, Heavy Chain)
RN  - 0 (SLC3A2 protein, human)
SB  - IM
MH  - Aged
MH  - Female
MH  - Fusion Regulatory Protein 1, Heavy Chain/*biosynthesis/genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - Lung Neoplasms/*metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Neuroendocrine Tumors/*metabolism/pathology
EDAT- 2011/07/14 06:00
MHDA- 2012/01/24 06:00
CRDT- 2011/07/14 06:00
PHST- 2011/05/11 00:00 [received]
PHST- 2011/06/14 00:00 [accepted]
PHST- 2011/07/14 06:00 [entrez]
PHST- 2011/07/14 06:00 [pubmed]
PHST- 2012/01/24 06:00 [medline]
AID - 10.3892/or.2011.1384 [doi]
PST - ppublish
SO  - Oncol Rep. 2011 Oct;26(4):931-7. doi: 10.3892/or.2011.1384. Epub 2011 Jul 11.